Radiopharmaceutical - Development Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2024
Radiopharmaceutical |
Albany, New York, Mar 22, 2017
"Radiopharmaceutical
Market - Global Industry Analysis, Size, Share, Growth, Trends and
Forecast 2017 - 2024"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
– Radiopharmaceutical
Market: Scope and Trends
This report on the radiopharmaceutical market
analyzes the current and future scenario of the global market.
Increase in incidence of various diseases, development of new sources
for radioisotope production, and rise in demand for nuclear medicine
are boosting the radiopharmaceutical market. Increase in incidence of
cancer and cardiovascular diseases, growth in awareness about
effective use of radiopharmaceuticals, and rise in preference for
SPECT and PET scans are some of the factors expected to drive the
growth of the global radiopharmaceutical market during the forecast
period.
The
radiopharmaceutical market report comprises an elaborate executive
summary, which includes market snapshot that provides information
about various segments. It also provides information and data
analysis of the global market with respect to the segments based on
radioisotopes, source, end-user, and geography. A detailed
qualitative analysis of drivers and restraints, and opportunities has
been provided in the market overview section. Additionally, the
section comprises Porters Five Forces Analysis to help understand the
competitive landscape in the market. This section also provides
market attractiveness analysis in terms of geography and market share
analysis by key players, thus presenting a thorough analysis of the
overall competitive scenario in the global radiopharmaceutical
market.
– Radiopharmaceutical Market:
Segmentation
Based on radioisotope, the market has been
segmented into Technetium-99, Lutetium-177, Rubidium-87, Iodine-123,
Yttrium-90, and Gallium-62. Technetium-99 is the most widely used
radioisotope across the globe; around 70% of radiopharmaceutical
companies depend on Mo-99 to produce Technetium-99, as per the World
Nuclear Association. The market segments have been analyzed based on
available approved products, cost-effectiveness, and preference for
technological systems by physicians and patients. The market size and
forecast for each of these segments have been provided for the period
from 2014 to 2024, along with their respective CAGRs for the forecast
period from 2017 to 2024, considering 2015 as the base year.
Based on source, the radiopharmaceutical market
has been segmented into two major categories: nuclear reactors and
cyclotrons. The market segments have been extensively analyzed based
on increase in demand for radioisotopes for nuclear medicines,
availability of radioisotopes and raw materials, radioisotopes short
half-life and number of production units used for production of
radioisotopes. Different types of end-user utilize
radiopharmaceutical products to treat diseases either through imaging
techniques or the therapeutics method.
Under the end-user segment, hospitals plays a
major role followed by ambulatory surgical centers, diagnostic
centers, and others (such as universities, research laboratories, and
pathology labs). The market size and forecast in terms of US$ Mn for
each segment have been provided for the period from 2014 to 2024. The
report also provides the compound annual growth rate (CAGR %) for
each market segment for the forecast period from 2017 to 2024,
considering 2015 as the base year. Application segment signifies the
usage of radiopharmaceutical products through different disease
indication such as oncology, cardiology, neurology, nephrology,
gastroenterology, immunology and others. Oncology segment is the
dominant sector which emphasizes the use of different radioisotopes
for treating various cancers and overcome the side effects of
therapeutics. Brachytherapy is a sub segment of oncology application
which signifies the methods of treating cancer through implants,
surgery or radiation technology. The segment is expected to have a
significant growth during the forecast period.
Geographically, the global radiopharmaceutical
market has been categorized into five major regions and the key
countries in the respective region: North America (the U.S. and
Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of
Europe), Asia Pacific (India, Japan, China, Australia, and Rest of
Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin
America) and Middle East & Africa (South Africa, Saudi Arabia,
and Rest of Middle East & Africa). The market size and forecast
for each of these regions and the mentioned countries have been
provided for the period from 2014 to 2024, along with their
respective CAGRs for the forecast period from 2017 to 2024,
considering 2015 as the base year.
– Radiopharmaceutical Market:
Competitive Landscape
The report also profiles major players in the
global radiopharmaceutical market based on various attributes such as
company overview, financial overview, product portfolio, business
strategies, SWOT analysis, and recent developments. Major players
profiled in this report include Advanced Accelerator Applications
(AAA), Eckert & Ziegler, GE Healthcare, IBA Radiopharma
Solutions, Lantheus Holdings, Inc., Mallinckrodt plc., Nordion, Inc.,
Siemens Healthineers, and Positron Corporation.
** The global radiopharmaceutical market has been
segmented as follows:
– Global Radiopharmaceutical Market, by
Radioisotope
- Technetium-99
- Gallium-67
- Iodine-123
- 18F
- Rubidium-82
- Yttrium-90
- Lutetium-177
– Global Radiopharmaceutical Market, by
Source
- Nuclear Reactors
- Cyclotrons
– Global Radiopharmaceutical Market, by
End-user
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
- Others
– Global Radiopharmaceutical Market, by
Application
- Cardiology
- Gastroenterology
- Oncology
- Brachytherapy
- Others
- Nephrology
- Neurology
- Immunology
- Others
– Global Radiopharmaceutical Market, by
Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
–
Table of Content
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global
Radiopharmaceutical Market
4. Market Overview
4.1. Introduction
4.1.1. Radioisotopes Definition
4.1.2. Industry Evolution / Developments
4.2.Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Radiopharmaceutical Market Analysis and Forecasts, 2014–2024
4.5.1. Market Revenue Projections (US$ Mn)
4.7. Porter’s Five Force Analysis
4.8. Value Chain Analysis
4.9. Market Outlook
4.9.1. FDA Approved Radiopharmaceutical Products, By Manufacturers & Trade Name
4.9.2. Market Size (US$ Mn) & Forecast, 2014-2024
4.9.3. Market Share (%), By Segments, 2017
4.9.4. Global Supply Demand Scenario, By Country, 2015
4.10. Application of Radiopharmaceutical (Peptide Receptor Radionuclide Therapy (PRRT) and Brachytherapy
4.1. Introduction
4.1.1. Radioisotopes Definition
4.1.2. Industry Evolution / Developments
4.2.Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Radiopharmaceutical Market Analysis and Forecasts, 2014–2024
4.5.1. Market Revenue Projections (US$ Mn)
4.7. Porter’s Five Force Analysis
4.8. Value Chain Analysis
4.9. Market Outlook
4.9.1. FDA Approved Radiopharmaceutical Products, By Manufacturers & Trade Name
4.9.2. Market Size (US$ Mn) & Forecast, 2014-2024
4.9.3. Market Share (%), By Segments, 2017
4.9.4. Global Supply Demand Scenario, By Country, 2015
4.10. Application of Radiopharmaceutical (Peptide Receptor Radionuclide Therapy (PRRT) and Brachytherapy
5. Global Radiopharmaceutical Market
Analysis and Forecasts, By Radioisotopes
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Analysis Forecast By Radioisotopes , 2014–2024
5.4.1. Technetium-99
5.4.2. Gallium-67
5.4.3. Iodine-123
5.4.4. Iodine-125
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Analysis Forecast By Radioisotopes , 2014–2024
5.4.1. Technetium-99
5.4.2. Gallium-67
5.4.3. Iodine-123
5.4.4. Iodine-125
Comments
Post a Comment